Within the pharmaceutical industry the assessment of dose-response is a critical part of a drug development program. This paper reviews how dose-response studies are designed and analyzed, and compares and contrasts this against regulatory requirements. The paper aims to show that current practices for processing dose-response data do not meet the expectations of regulatory bodies. Alternative methods will be suggested.
RubergSJ. Dose Response Studies. Some Design Considerations. J Biopharma Stat.1995;5:1–14.
2.
SnedecorGWCochranWG. Statistical Methods.Iowa: Iowa State University Press; 1967: Chapters 9 and 12.
3.
DuncanDB. Multiple Range and Multiple F tests. Biometrics.1955;11:1–42.
4.
DunnettCW. A Multiple Comparison Procedure for Comparing Several Treatments with a Control. J Am Stat Assn.1955;56:52–64.
5.
WilliamsDA. A Test for Differences between Treatment Means When Several Dose Levels are Compared with A Zero Dose Control. Biometrics.1971; 27:103–177.
6.
WilliamsDJ. The Comparison of Several Dose Levels with a Zero Dose Control. Biometrics.1972;28: 519–531.
7.
BartholomewDJ. A Test of Homogeneity for Ordered Alternatives. Biometrika.1959;46:36–48.
8.
BartholomewDJ. A Test of Homogeneity for Ordered Alternatives II. Biometrika.1959;46:328–335.
9.
BartholomewDJ. A Test of Homogeneity of Means Under Restricted Alternatives. J Roy Stat Soc. Series B.1961;23:239–281.
10.
JonckheereAR. A Distribution-Free K Sample Test Against Ordered Alternatives. Biometrika.1954;41: 133–145.
11.
ChackoVJ. Testing homogeneity against ordered alternatives. Ann Math Stat.1963;34:945–956.
12.
ChaseGR. On testing for ordered alternatives with increased sample size for a control. Biometrika.1974;61:569–578.
13.
ShirleyEAC. The Value of Specialised Tests in Studies Where Ordered Group Means Are Expected. Stat Med.1985;4:489–496.
14.
Food and Drug Administration.Clinical and Statistical Section of a New Drug Application. Rockville, MD: Food and Drug Administration; 1988.
15.
Committee for Propriety Medicinal Products.Bio-statistical Methodology in Clinical Trials in Application for Marketing Authorization for Medicinal Products. Brussels: Committee for Proprietary Medicine; 1994.
16.
International Conference on Harmonisation.Dose-Response Information to Support Drug Registration; 1994.
